leisure time -WSS

leisure time

author：comprehensive 2025-09-29 21:02:25 - browse：7

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Carbon Health diabetes program, a test of data

entertainment

leisure time

WSS

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medicare Advantage coverage denials need scrutiny, senators say

American taxpayers paid $1.8 trillion in health care costs in 2022

Arena BioWorks launches in Cambridge to speed drug discovery

focus

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Psychedelics group wrestles with new pharma identity

Stories you might have missed in 2023: health, science, medicine

Virginia high school admissions case could be legal follow

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Alkermes shareholders re

Ascension's ugly legal battle over care for poor patients in Texas

In age of alternative facts, a scholarly course on calling out crap

Healthy food access boosts outcomes in two studies

hotspot

Medicare Advantage overpayments discussion gets experts fired up

FDA early review: GLP

STAT Virtual Event: JPM Recap, Live!

Experimental asthma app from Apple and Anthem shows promise

Merck to acquire Harpoon Therapeutics for $680 million

White House drug czar issues call for 'recovery

focus

entertainment

leisure time

hotspot